Dr. Carleton’s lifelong goal is to make medication use more effective and safer for all patients, particularly children. His research focus is on the impact of drug therapy on human health and quality of life. He is particularly interested in developing better ways to evaluate the effectiveness of drugs, medication-use models designed to improve patient health, as well as practical surveillance systems to improve the safe use of medication.
A key element of Dr. Carleton’s research is the communication of results to clinicians, patients, healthcare administrators, and government officials – those who also hold responsibilities to improve patient care and our systems of healthcare delivery.
Dr. Carleton earned his Bachelor degree in pharmaceutical sciences in 1986 from Washington State University. He continued at the University of Utah, earning his Doctorate in Pharmacy degree in 1989. After completing a Residency in Clinical Therapeutics at the University of Utah and Primary Children’s Medical Centers, he accepted a post-doctoral Fellowship at the University of Minnesota focusing on Experimental Therapeutics. Dr. Carleton completed a second Fellowship in Immunopharmacology at the University of Minnesota Transplant Center, and then joined the faculty at the University of British Columbia in 1991.
In addition to his appointment as Professor of Paediatrics and Co-Chair of the Division of Translational Therapeutics, Department of Pediatric Medicine at UBC, Dr. Carleton is a Senior Clinician Scientist at the Child & Family Research Institute. He directs the Pharmaceutical Outcomes Programme at BC Children’s Hospital and he has served in this capacity since 1994. He holds appointments at UBC in the Centre for Health Services and Policy Research, the School of Population & Public Health and the Faculty of Pharmaceutical Sciences and the School of Health Information Science, University of Victoria. Dr. Carleton’s public service is expansive. It includes serving as a charter member on the national Canadian Expert Drug Advisory Committee. Dr. Carleton was recently asked to serve the US Government as a Special Government Employee to advise the Advisory Committee for Pharmaceuticals and Clinical Pharmacology of the FDA.